McDermott M T, Hofeldt F D, Kidd G S
Department of Medicine, Fitzsimons Army Medical Center, Aurora, CO 80045-5001.
South Med J. 1990 Nov;83(11):1283-5. doi: 10.1097/00007611-199011000-00013.
We have evaluated the efficacy of the antiestrogen tamoxifen in six men with painful idiopathic gynecomastia. Subjects were given either tamoxifen or placebo for 2 to 4 months and then were given the other agent for an identical period. Breast size was considered to have been reduced only if it had decreased by one or more Marshall-Tanner stages during the treatment period. Pain reduction with tamoxifen therapy was statistically significant for the group, occurring in five of six subjects during tamoxifen treatment and in only one of six during the placebo period. Size reduction with tamoxifen was only marginally significant for the entire group, but occurred in all three subjects who were initially in Marshall-Tanner stage III and in none of the three subjects who were initially in stage V. During tamoxifen treatment, there was a significant increase in the serum levels of luteinizing hormone and total estradiol and a marginally significant increment in the total testosterone level.
我们评估了抗雌激素药物他莫昔芬对6名患有疼痛性特发性男性乳房肥大症男性的疗效。受试者接受他莫昔芬或安慰剂治疗2至4个月，然后再接受另一种药物相同疗程的治疗。只有在治疗期间乳房大小下降了一个或多个马歇尔-坦纳分期时，才认为乳房大小有所减小。他莫昔芬治疗组的疼痛减轻具有统计学意义，6名受试者中有5名在接受他莫昔芬治疗期间疼痛减轻，而在接受安慰剂治疗期间6名中只有1名疼痛减轻。他莫昔芬治疗使整个组的乳房大小减小仅略有统计学意义，但最初处于马歇尔-坦纳III期的3名受试者中所有受试者的乳房大小均减小，而最初处于V期的3名受试者中无一人乳房大小减小。在他莫昔芬治疗期间，促黄体生成素和总雌二醇的血清水平显著升高，总睾酮水平略有升高。
